Pharma News, 2025

AbbVie  recently secured FDA approval for RINVOQ (Upadacitinib) to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company&...

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Pfizer’s sasanlimab improves event-free survival in phase 3 bladder cancer trial

The European Commission (EC) has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for treating Duchenne muscular dystrophy (DMD).

Gilead Sciences’ stock is up 12% this year, topping a 1% gain for the NYSE Arca Pharmaceutical Index.  Chief Executives don’t usually brag about paying high tax rates.

Ipsen’s elafibranor (sold under the brand name Iqirvo) has shown promise as a treatment for primary sclerosing cholangitis (PSC),

Eli Lilly's New Weight Loss Drug May Have the Worst Name in Pharmaceutical Histrory

Early treatment with Ocrevus (ocrelizumab) may help protect the cerebellum, a region of the brain that plays a key role in motor coordination

Thermo Fisher Scientific to invest $2bn into US manufacturing capabilities

Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress

Equillium Announces Feedback from the U.S. Food and Drug Administration

Veraxa to go public in $1.6bn SPAC deal with Voyager